Sector: Pharmaceuticals
IN_AUROPHARMA
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: yahoo_fundamentals_timeseries/AUROPHARMA.NS
Monetary columns are in B INR, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueB INR | Operating profitB INR | D&AB INR | EBITDAB INR | Net profitB INR | Operating CFB INR | Capex + M&AB INR | AssetsB INR | EquityB INR | ROE (annualized) | Net debtB INR | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Q2 2026 (3M) | PARTIAL | 91.1 y/y 16.9% | 13.9 y/y 16.4% | 4.9 y/y 20.0% | 18.8 y/y 17.3% | 10.3 y/y 25.2% | — | — | — y/y — | 378.8 y/y 16.0% | 10.9% | ≈ 4.8 | — |
| 2026-03-31 | FY 2026 (12M) | OK | — y/y 6.4% | — y/y 2.9% | — y/y 10.6% | — y/y 4.7% | — y/y 0.5% | — | — | 585.0 y/y 17.5% | 378.9 y/y 16.0% | 9.6% | 4.8 | — |
| 2025-12-31 | Q4 2025 (3M) | PARTIAL | 86.0 y/y 7.8% | 13.1 y/y 8.2% | 4.6 y/y — | 17.7 y/y 46.6% | 9.1 y/y 7.6% | — | — | — y/y — | 350.3 y/y 13.4% | 3.5% | ≈ -78.5 | — |
| 2025-09-30 | Q3 2025 (3M) | OK | 82.9 y/y 6.3% | 12.5 y/y 5.5% | 3.5 y/y — | 16.0 y/y 34.9% | 8.5 y/y 3.8% | — | — | 525.5 y/y 9.3% | 350.3 y/y 13.4% | 10.0% | -78.5 | Link |
| 2025-06-30 | Q2 2025 (3M) | PARTIAL | 77.9 y/y 3.0% | 12.0 y/y -1.5% | 4.1 y/y — | 16.0 y/y 31.9% | 8.2 y/y -10.3% | — | — | — y/y — | 326.5 y/y 9.4% | 10.1% | ≈ 23.7 | — |
| 2025-03-31 | FY 2025 (12M) | OK | — y/y 9.3% | — y/y 13.7% | — y/y 4.6% | — y/y 11.3% | — y/y 9.9% | — | — | 497.8 y/y 10.5% | 326.5 y/y 9.4% | 11.0% | 23.7 | — |
| 2024-12-31 | Q4 2024 (3M) | PARTIAL | 79.8 y/y 8.5% | 12.1 y/y 2.7% | — y/y — | 12.1 y/y 2.7% | 8.5 y/y -9.7% | — | — | — y/y — | 308.8 y/y 9.5% | 3.7% | ≈ -48.9 | Link |
| 2024-09-30 | Q3 2024 (3M) | OK | 78.0 y/y 8.0% | 11.8 y/y 20.1% | — y/y — | 11.8 y/y 20.1% | 8.2 y/y 8.0% | — | — | 480.9 y/y 9.5% | 308.8 y/y 9.5% | 10.8% | -48.9 | Link |
| 2024-06-30 | Q2 2024 (3M) | PARTIAL | 75.7 y/y — | 12.2 y/y — | — y/y — | 12.2 y/y — | 9.2 y/y — | — | — | — y/y — | 298.5 y/y — | 12.3% | ≈ 29.1 | Link |
| 2024-03-31 | FY 2024 (12M) | OK | — y/y 16.6% | — y/y 75.0% | — y/y 22.3% | — y/y 57.7% | — y/y 64.6% | — | — | 450.7 y/y 13.0% | 298.4 y/y 11.2% | 10.9% | 29.2 | — |
| 2023-12-31 | Q4 2023 (3M) | PARTIAL | 73.5 y/y — | 11.8 y/y — | — y/y — | 11.8 y/y — | 9.4 y/y — | — | — | — y/y — | 281.9 y/y — | 4.4% | ≈ -53.6 | Link |
| 2023-09-30 | Q3 2023 (3M) | OK | 72.2 y/y — | 9.9 y/y — | — y/y — | 9.9 y/y — | 7.6 y/y — | — | — | 439.2 y/y — | 281.9 y/y — | 11.0% | -53.6 | Link |
| 2023-03-31 | FY 2023 (12M) | OK | 246.2 y/y — | 25.4 y/y — | 12.4 y/y — | 37.8 y/y — | 19.3 y/y — | 23.9 | -27.2 | 398.9 y/y — | 268.4 y/y — | — | 4.7 | — |
Quarterly values (INR mln)
Year-over-year change
Net debt / cash (INR mln)
| year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| cash flow / profit | 1.89x | 1.24x | 0.77x | 1.13x | 1.58x |
| accruals, % of assets | — | -1.1% | 1.6% | -0.9% | -3.5% |
Value the company creates per year, as a % of market cap
Value created per year: +15.2%
| 1. EBITDA growth (latest quarter YoY, annualised) [EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30) = (18 811 − 16 034) × 3.75 | 10 409 |
| 2. Current EV/EBITDA (LTM) (Market cap + Net debt) ÷ EBITDA (LTM) = (977 663 + 4 848) ÷ 70 524 | 13.9x |
| 3. Target multiple (Current EV/EBITDA + 11) ÷ 2 = (13.9 + 11) ÷ 2 | 12.5x |
| 4. Cash flow (balance method, LTM) Net-debt reduction + dividends + buybacks − equity issuance = 18 879 + 0 + 0 − 0 | 18 879 |
| 5. Value created per year (EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap = (10 409 × 12.5 + 18 879) ÷ 977 663 | +15.2% |
Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.
Caveats:
| Date | Per share | Details | Status | Source |
|---|---|---|---|---|
| 2025-08-08 | 4 INR | Ex-dividend: 4 INR per share | Paid | Yahoo Finance (ex-div) |
| 2024-02-20 | 1.5 INR | Ex-dividend: 1.5 INR per share | Paid | Yahoo Finance (ex-div) |
| 2023-11-20 | 3 INR | Ex-dividend: 3 INR per share | Paid | Yahoo Finance (ex-div) |
| 2023-02-17 | 3 INR | Ex-dividend: 3 INR per share | Paid | Yahoo Finance (ex-div) |
| 2022-06-06 | 4.5 INR | Ex-dividend: 4.5 INR per share | Paid | Yahoo Finance (ex-div) |
| 2022-02-18 | 1.5 INR | Ex-dividend: 1.5 INR per share | Paid | Yahoo Finance (ex-div) |
| 2021-11-17 | 1.5 INR | Ex-dividend: 1.5 INR per share | Paid | Yahoo Finance (ex-div) |
KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)
Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Aurobindo Pharma (AUROPHARMA) — from primary filings.
See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map